EDMA , the European Diagnostic Manufacturers Association welcomes SEBIA as new corporate affiliate, bringing the Association's overall membership up to 33 major IVD companies and 21 National Associations.
SEBIA aims at improving clinical electrophoresis laboratories by increasing productivity and quality through improved traditional and innovative electrophoresis assays.
Since its establishment in 1967, SEBIA has been 100% dedicated to the science of electrophoresis, the process that allows separating and characterizing molecules in an applied electric field and thus used for the analysis of proteins present in the serum or in other biological fluids. The electrophoresis technology is very helpful for the diagnosis of pathologies related to cancer, the search of immune system abnormality or for the detection of haemoglobin variants.
With at least 10% of its annual budget dedicated to research and development, SEBIA has contributed to the improvement of the electrophoresis diagnosis applications. Major innovations in both the reagents and instruments fields have been launched. The most recent developments in the capillary electrophoresis technology have led to achieve a full walk-away automation and an enhanced traceability.
Its philosophy focuses on offering outstanding value with constant improvement in products, service and support, including the production of a full range of educational materials about the electrophoresis field .
EDMA looks forward to cooperating with SEBIA, its new corporate member, so that the enhancement of technology and healthcare will continue to provide people with the most cost-effective, well equipped and advanced products on the market.